Crovalimab (SKY59; RO7112689) is a novel humanized monoclonal antibody designed to target complement component 5 (C5) in a pH-dependent manner. It exhibits dissociation constants (K_D) of 15.2 nM at pH 7.4 and 16.8 μM at pH 5.8, reflecting its pH-responsive binding affinity. Additionally, Crovalimab demonstrates strong binding to human FcRn with a K_D of 17 μM at pH 6.0. This antibody effectively blocks the cleavage of C5 by C5 convertase and inhibits the activity of a specific C5 variant characterized by the p.Arg885His mutation. Furthermore, Crovalimab significantly inhibits the formation of the terminal complement complex C5b-9 across all three complement pathways: classical, lectin, and alternative. Due to these properties, Crovalimab is of significant interest for research into paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases, offering potential insights into novel therapeutic approaches.
Crovalimab (SKY59; RO7112689) is a novel humanized monoclonal antibody designed to target complement component 5 (C5) in a pH-dependent manner. It exhibits dissociation constants (K_D) of 15.2 nM at pH 7.4 and 16.8 μM at pH 5.8, reflecting its pH-responsive binding affinity. Additionally, Crovalimab demonstrates strong binding to human FcRn with a K_D of 17 μM at pH 6.0. This antibody effectively blocks the cleavage of C5 by C5 convertase and inhibits the activity of a specific C5 variant characterized by the p.Arg885His mutation. Furthermore, Crovalimab significantly inhibits the formation of the terminal complement complex C5b-9 across all three complement pathways: classical, lectin, and alternative. Due to these properties, Crovalimab is of significant interest for research into paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases, offering potential insights into novel therapeutic approaches.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
